News

With its unique mechanism, the novel drug represents a potentially important option for subgroups of patients with Graves’ disease who either don’t respond to antithyroid medications such as ...
Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant. In a phase 2a trial ...
Compared with adults receiving only antithyroid drug therapy, those who underwent a thyroidectomy had lower risks for all-cause mortality (HR = 0.363; 95% CI, 0.332-0.396), CVD ...
They identified 62,474 patients in the UK population-based electronic health record database who had newly diagnosed hyperthyroidism and were treated with antithyroid drugs (73.4%), radioiodine ...